help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target ...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ross, J. S.
Right arrow Articles by Bloom, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ross, J. S.
Right arrow Articles by Bloom, K. J.
The Oncologist, Vol. 8, No. 4, 307–325, August 2003
© 2003 AlphaMed Press

ORIGINAL PAPER
Breast Cancer

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

Jeffrey S. Rossa,b, Jonathan A. Fletcherc, Gerald P. Linetteb,d, James Stecb, Edward Clarkb, Mark Ayersb, W. Fraser Symmanse, Lajos Pusztaie, Kenneth J. Bloomf

a Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA; b Division of Molecular Medicine, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA; c Department of Pathology, Brigham Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; d Department of Medicine, Washington University, St. Louis, Missouri, USA; e Departments of Medicine and Pathology, M.D. Anderson Cancer Center, Houston, Texas, USA; f US Labs, Inc., Irvine, California, USA

Correspondence: Jeffrey S. Ross, M.D., Albany Medical College, Department of Pathology, Mail Code 81, 47 New Scotland Avenue, Albany, New York 12208, USA. Telephone: 518-262-5461; Fax: 518-262-8092; e-mail: rossj{at}mail.amc.edu

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages and disadvantages of Southern blotting, polymerase chain reaction amplification, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is presented as well as its potential impact on responses to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review also evaluates the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.

Key Words. Trastuzumab • IHC • FISH • Prognosis • review




This article has been cited by other articles:


Home page
 CarcinogenesisHome page
X. Meng, S. F. Shoemaker, S. O. McGee, and M. M. Ip
t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways
Carcinogenesis, May 1, 2008; 29(5): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso
HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer
Ann. Onc., February 1, 2008; 19(2): 223 - 232.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
M. Kroese, R. L Zimmern, and S. E Pinder
HER2 status in breast cancer--an example of pharmacogenetic testing
J R Soc Med, July 1, 2007; 100(7): 326 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al.
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mol. Cancer Ther., July 1, 2007; 6(7): 2065 - 2072.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Gori, S. Rimondini, V. De Angelis, M. Colozza, G. Bisagni, G. Moretti, A. Sidoni, C. Basurto, C. Aristei, P. Anastasi, et al.
Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors
Oncologist, July 1, 2007; 12(7): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. F. R. Robertson
Fulvestrant (Faslodex(R)) How to Make a Good Drug Better
Oncologist, July 1, 2007; 12(7): 774 - 784.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson
The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C. Barrett, H. Magee, D. O'Toole, S. Daly, and M. Jeffers
Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
J. Clin. Pathol., June 1, 2007; 60(6): 690 - 693.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. S. Ross, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes
Clin. Cancer Res., May 15, 2007; 13(10): 2831 - 2835.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A Di Leo
The state of HER-2 status
Ann. Onc., May 1, 2007; 18(5): 813 - 815.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A Goldhirsch, A. Coates, R. Gelber, J. Glick, B Thurlimann, H-J Senn, and On behalf of the St Gallen Expert Panel Members
First--select the target: better choice of adjuvant treatments for breast cancer patients
Ann. Onc., December 1, 2006; 17(12): 1772 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Vocaturo, F. Novelli, M. Benevolo, G. Piperno, F. Marandino, A. M. Cianciulli, R. Merola, R. P. Donnorso, I. Sperduti, S. Buglioni, et al.
Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep(R)-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era
Oncologist, September 1, 2006; 11(8): 878 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Yaal-Hahoshen, S. Shina, L. Leider-Trejo, I. Barnea, E. L. Shabtai, E. Azenshtein, I. Greenberg, I. Keydar, and A. Ben-Baruch
The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients
Clin. Cancer Res., August 1, 2006; 12(15): 4474 - 4480.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
J. Clin. Oncol., June 1, 2006; 24(16): 2428 - 2436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Morrison, V. Zanagnolo, N. Ramirez, D. E. Cohn, N. Kelbick, L. Copeland, L. G. Maxwell, and J. M. Fowler
HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2376 - 2385.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. B. Ershler
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Oncologist, April 1, 2006; 11(4): 325 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. A. Lazar, W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al.
Engineered antibody Fc variants with enhanced effector function.
PNAS, March 14, 2006; 103(11): 4005 - 4010.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Kauraniemi and A Kallioniemi
Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. A. Cahill, D. Walsh, R. J. Landers, and R. G. Watson
Preoperative Profiling of Symptomatic Breast Cancer by Diagnostic Core Biopsy
Ann. Surg. Oncol., January 1, 2006; 13(1): 45 - 51.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. R Kell and C. P Power
Adjuvant trastuzumab for breast cancer: Assessing HER2/neu status incurs more costs for treatment
BMJ, November 19, 2005; 331(7526): 1202 - 1202.
[Full Text] [PDF]

Home page
 JCOHome page
E. Espinosa, J.A. F. Vara, A. Redondo, J.J. Sanchez, D. Hardisson, P. Zamora, F. G. Pastrana, P. Cejas, B. Martinez, A. Suarez, et al.
Breast Cancer Prognosis Determined by Gene Expression Profiling: A Quantitative Reverse Transcriptase Polymerase Chain Reaction Study
J. Clin. Oncol., October 10, 2005; 23(29): 7278 - 7285.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc., October 1, 2005; 16(10): 1569 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. J. Gilbertson
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Oncologist, August 1, 2005; 10(7): 508 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Tse, D. Brault, J. Gligorov, M. Antoine, R. Neumann, J.-P. Lotz, and J. Capeau
Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients
Clin. Chem., July 1, 2005; 51(7): 1093 - 1101.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ma, L. Lespagnard, V. Durbecq, M. Paesmans, C. Desmedt, M. Gomez-Galdon, I. Veys, F. Cardoso, C. Sotiriou, A. Di Leo, et al.
Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice
Clin. Cancer Res., June 15, 2005; 11(12): 4393 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma
J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Lafky, A. T. Baron, E. M. Cora, D. W. Hillman, V. J. Suman, E. A. Perez, J. N. Ingle, and N. J. Maihle
Serum Soluble Epidermal Growth Factor Receptor Concentrations Decrease in Postmenopausal Metastatic Breast Cancer Patients Treated with Letrozole
Cancer Res., April 15, 2005; 65(8): 3059 - 3062.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Carter, L. Smith, and M. Ryan
Identification and validation of cell surface antigens for antibody targeting in oncology
Endocr. Relat. Cancer, December 1, 2004; 11(4): 659 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Croci, G. Nicoletti, L. Landuzzi, C. De Giovanni, A. Astolfi, C. Marini, E. Di Carlo, P. Musiani, G. Forni, P. Nanni, et al.
Immunological Prevention of a Multigene Cancer Syndrome
Cancer Res., November 15, 2004; 64(22): 8428 - 8434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Milella, D. Trisciuoglio, T. Bruno, L. Ciuffreda, M. Mottolese, A. Cianciulli, F. Cognetti, U. Zangemeister-Wittke, D. Del Bufalo, and G. Zupi
Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene-Amplified Breast Cancer Cells
Clin. Cancer Res., November 15, 2004; 10(22): 7747 - 7756.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. F. Solca, A. Baum, E. Langkopf, G. Dahmann, K.-H. Heider, F. Himmelsbach, and J. C. A. van Meel
Inhibition of Epidermal Growth Factor Receptor Activity by Two Pyrimidopyrimidine Derivatives
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 502 - 509.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Osborne, P. Wilson, and D. Tripathy
Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications
Oncologist, July 1, 2004; 9(4): 361 - 377.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. L. Wiley and L. K. Diaz
High-Quality HER-2 Testing: Setting a Standard for Oncologic Biomarker Assessment
JAMA, April 28, 2004; 291(16): 2019 - 2020.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. E. Celis, P. Gromov, T. Cabezon, J. M. A. Moreira, N. Ambartsumian, K. Sandelin, F. Rank, and I. Gromova
Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment: A Novel Resource for Biomarker and Therapeutic Target Discovery
Mol. Cell. Proteomics, April 1, 2004; 3(4): 327 - 344.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Tripathy, D. J. Slamon, M. Cobleigh, A. Arnold, M. Saleh, J. E. Mortimer, M. Murphy, and S. J. Stewart
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
J. Clin. Oncol., March 15, 2004; 22(6): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. G. Kirsch and F. H. Hochberg
Targeting HER2 in Brain Metastases from Breast Cancer
Clin. Cancer Res., November 15, 2003; 9(15): 5435 - 5436.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2003 by AlphaMed Press.